AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34044738 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing exercise program
Number of subjects: 90
Study 34044738 — intervention group
Group type: COMPARATOR
Intervention: Control group (incentive spirometer)
Number of subjects: 90
Study 34044738 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 33638661 — intervention group
Group type: EXPERIMENTAL
Intervention: Amyloid-PET (first exam)
Number of subjects: 136
Study 33638661 — intervention group
Group type: EXPERIMENTAL
Intervention: Tau-PET (first exam)
Number of subjects: 136
Study 33638661 — intervention group
Group type: EXPERIMENTAL
Intervention: Amyloid-PET (second exam)
Number of subjects: 136
Study 33638661 — intervention group
Group type: EXPERIMENTAL
Intervention: Tau-PET (second exam)
Number of subjects: 136
Study 32758761 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing with initial breakage (N=1)
Number of subjects: 31
Study 36202725 — intervention group
Group type: EXPERIMENTAL
Intervention: TAHSNp Health Professions Innovation Fellowship program
Number of subjects: 25
Study 33946717 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise referral schemes and self‐management strategies
Number of subjects: 83
Study 33946717 — intervention group
Group type: COMPARATOR
Intervention: Control group participants
Number of subjects: 83
Study 35078923 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemoimmunotherapy followed by chemotherapy-free radioimmunotherapy (RIT)
Number of subjects: 79
Study 35078923 — intervention group
Group type: EXPERIMENTAL
Intervention: RIT cohort (n=60)
Number of subjects: 79
Study 35078923 — intervention group
Group type: EXPERIMENTAL
Intervention: RIT for HPV-positive oropharyngeal cancers
Number of subjects: 79
Study 35078923 — intervention group
Group type: EXPERIMENTAL
Intervention: RIT for HPV-negative oropharyngeal cancers and other locations
Number of subjects: 79
Study 35078923 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire study cohort (n=79)
Number of subjects: 79
Study 35078923 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicity grade 3-4
Number of subjects: 79
Study 33787533 — intervention group
Group type: EXPERIMENTAL
Intervention: XGBoost model for early mortality prediction
Number of subjects: 938
Study 33787533 — intervention group
Group type: COMPARATOR
Intervention: Logistic regression model
Number of subjects: 938
Study 33787533 — intervention group
Group type: COMPARATOR
Intervention: Support vector machine model
Number of subjects: 938
Study 33787533 — intervention group
Group type: COMPARATOR
Intervention: Random forest model
Number of subjects: 938
Study 33787533 — intervention group
Group type: COMPARATOR
Intervention: Naive Bayesian model
Number of subjects: 938
Study 33787533 — intervention group
Group type: COMPARATOR
Intervention: Sequential Organ Failure Assessment score
Number of subjects: 938
Study 33787533 — intervention group
Group type: COMPARATOR
Intervention: Acute Physiology Score III
Number of subjects: 938
Study 32392996 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Pulsed Ultrasound (LIPUS) applied 3 times per week
Number of subjects: 40
Study 32392996 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Pulsed Ultrasound (LIPUS) applied 2 times per week
Number of subjects: 40
Study 35191065 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-type block bone substitute (synthetic biphasic calcium phosphate + collagen)
Number of subjects: 40
Study 35191065 — intervention group
Group type: COMPARATOR
Intervention: Particulate bone substitute (biphasic calcium phosphate)
Number of subjects: 40
Study 33227223 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine hydrochloride film
Number of subjects: 0
Study 33227223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34882063 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular cycle variability (>6 days)
Number of subjects: 3473
Study 34882063 — intervention group
Group type: COMPARATOR
Intervention: Regular cycle variability (≤6 days)
Number of subjects: 3473
Study 32776464 — intervention group
Group type: EXPERIMENTAL
Intervention: L-citrulline (CIT) supplementation (6g/day)
Number of subjects: 24
Study 32776464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 33109739 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 years of extended letrozole
Number of subjects: 908
Study 33109739 — intervention group
Group type: COMPARATOR
Intervention: 2.5 years of extended letrozole
Number of subjects: 908
Study 32348442 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal jet group (DJG, n=25)
Number of subjects: 71
Study 32348442 — intervention group
Group type: EXPERIMENTAL
Intervention: Jones jig group (JJG, n=30)
Number of subjects: 71
Study 32348442 — intervention group
Group type: COMPARATOR
Intervention: First Class group (FCG, n=16)
Number of subjects: 71
Study 35616421 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min group
Number of subjects: 90
Study 35616421 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 min group
Number of subjects: 90
Study 35616421 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 min group
Number of subjects: 90
Study 34074559 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pembrolizumab
Number of subjects: 0
Study 34074559 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib plus nivolumab
Number of subjects: 0
Study 34074559 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib plus pembrolizumab
Number of subjects: 0
Study 34074559 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab plus nivolumab
Number of subjects: 0
Study 34074559 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors + ICI combinations
Number of subjects: 0
Study 34074559 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual immunotherapy of ipilimumab and nivolumab
Number of subjects: 0
Study 32527166 — intervention group
Group type: EXPERIMENTAL
Intervention: Family empowerment through educational interventions
Number of subjects: 33
Study 32527166 — intervention group
Group type: COMPARATOR
Intervention: Nonstructural education
Number of subjects: 33
Study 35578303 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged requirement for insulin (PRI) on Day 5
Number of subjects: 476
Study 35578303 — intervention group
Group type: COMPARATOR
Intervention: No prolonged requirement for insulin (non-PRI)
Number of subjects: 476
Study 35578303 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged requirement for insulin (PRI) without glycemic control
Number of subjects: 476
Study 35578303 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged requirement for insulin (PRI) with glycemic control
Number of subjects: 476
Study 33156692 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot core strengthening protocol (8-week training course focused on foot-ankle muscles)
Number of subjects: 118
Study 33156692 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 118
Study 36252091 — intervention group
Group type: EXPERIMENTAL
Intervention: HF TENS
Number of subjects: 60
Study 36252091 — intervention group
Group type: EXPERIMENTAL
Intervention: LF TENS
Number of subjects: 60
Study 36252091 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 60
Study 33433786 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary IORT (IORT at the time of lumpectomy)
Number of subjects: 667
Study 33433786 — intervention group
Group type: EXPERIMENTAL
Intervention: Unintended boost (primary IORT followed by whole-breast radiation)
Number of subjects: 667
Study 33433786 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed IORT (after lumpectomy)
Number of subjects: 667
Study 33433786 — intervention group
Group type: EXPERIMENTAL
Intervention: Intended boost
Number of subjects: 667
Study 33433786 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary IORT with compliance to endocrine therapy
Number of subjects: 667
Study 33433786 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncompliance with endocrine therapy
Number of subjects: 667
Study 32375773 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling based on the WOMAN‐PRO II program
Number of subjects: 49
Study 32375773 — intervention group
Group type: COMPARATOR
Intervention: Written information
Number of subjects: 49
Study 32375773 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 49
Study 32375773 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 49
Study 32375773 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling time
Number of subjects: 49
Study 32375773 — intervention group
Group type: EXPERIMENTAL
Intervention: Local recurrence
Number of subjects: 49
Study 32012129 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500mg weekly)
Number of subjects: 187
Study 32012129 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200mg weekly)
Number of subjects: 187
Study 32012129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 35931968 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-designed HIIT workouts for 8 weeks
Number of subjects: 3
Study 35931968 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT Only group using co-designed HIIT workouts for 8 weeks
Number of subjects: 3
Study 35931968 — intervention group
Group type: COMPARATOR
Intervention: Control group continuing regular HPE lessons
Number of subjects: 3
Study 35931968 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-designed HIIT workouts
Number of subjects: 3
Study 33017209 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial Artery (RA)
Number of subjects: 619
Study 33017209 — intervention group
Group type: COMPARATOR
Intervention: Right Internal Thoracic Artery (RITA)
Number of subjects: 619
Study 33017209 — intervention group
Group type: COMPARATOR
Intervention: Saphenous Vein (SV)
Number of subjects: 619
Study 35194663 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG fluorescence cholangiography (ICG‐FC)
Number of subjects: 92
Study 35194663 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy
Number of subjects: 92
Study 33676596 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine Cool Mint
Number of subjects: 343
Study 33676596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study 33676596 — intervention group
Group type: COMPARATOR
Intervention: Listerine Cool Mint and Placebo
Number of subjects: 343
Study 35369700 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ablation (within 2 months from shock delivery)
Number of subjects: 517
Study 35369700 — intervention group
Group type: COMPARATOR
Intervention: Continuation of standard therapy (control group)
Number of subjects: 517
Study 32126840 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated personalized feedback intervention for anxiety sensitivity/hazardous drinking
Number of subjects: 130
Study 32126840 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 130
Study 32994239 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1
Number of subjects: 520
Study 32994239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study 32693046 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant AF ablation
Number of subjects: 1675
Study 35420393 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative bilateral transversus abdominis plane block (TAPB) and nalbuphine
Number of subjects: 0
Study 35420393 — intervention group
Group type: COMPARATOR
Intervention: Nalbuphine
Number of subjects: 0
Study 35420393 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 0
Study 34168295 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes nutrition education (two educational sessions of 30 min each)
Number of subjects: 100
Study 34168295 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 100
Study 33098709 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS: 10 min of 2 mA
Number of subjects: 32
Study 33098709 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS: 20 s of 2 mA
Number of subjects: 32
Study 33098709 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-study guess
Number of subjects: 32
Study 36131010 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol users
Number of subjects: 9252
Study 36131010 — intervention group
Group type: COMPARATOR
Intervention: Non-users of allopurinol
Number of subjects: 9252
Study 34910143 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA-IM)
Number of subjects: 4062
Study 34910143 — intervention group
Group type: COMPARATOR
Intervention: Copper intrauterine device (IUD)
Number of subjects: 4062
Study 34910143 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel (LNG) implant
Number of subjects: 4062
Study 34910143 — intervention group
Group type: COMPARATOR
Intervention: DMPA-IM vs Copper IUD
Number of subjects: 4062
Study 34910143 — intervention group
Group type: COMPARATOR
Intervention: DMPA-IM vs LNG implant
Number of subjects: 4062
Study 34910143 — intervention group
Group type: COMPARATOR
Intervention: Copper IUD vs LNG implant
Number of subjects: 4062
Study 34910143 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV acquisition during follow-up
Number of subjects: 4062
Study 35379621 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatekeeper training intervention for vendors
Number of subjects: 2700000
Study 34588210 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 163
Study 34588210 — intervention group
Group type: COMPARATOR
Intervention: Blood Glucose Monitoring (BGM)
Number of subjects: 163
Study 34588210 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) continued
Number of subjects: 163
Study 34273442 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond Elect (PB) in self-etch (SE) mode
Number of subjects: 54
Study 34273442 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal Adhesive (SBU) in etch-and-rinse (ER) mode
Number of subjects: 54
Study 34273442 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal Adhesive (SBU) in self-etch (SE) mode
Number of subjects: 54
Study 34273442 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond Elect (PB) in etch-and-rinse (ER) mode
Number of subjects: 54
Study 34535409 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling (DN) of the obliquus capitis inferior (OCI)
Number of subjects: 40
Study 34535409 — intervention group
Group type: COMPARATOR
Intervention: Sham needling of the obliquus capitis inferior (OCI)
Number of subjects: 40
Study 34535409 — intervention group
Group type: COMPARATOR
Intervention: Both groups (DN and sham)
Number of subjects: 40
Study 35027415 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture group
Number of subjects: 72
Study 35027415 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture group
Number of subjects: 72
Study 35027415 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (verum and sham acupuncture)
Number of subjects: 72
Study 33662102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin, 300 µg/kg per day for 5 days
Number of subjects: 400
Study 33662102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 33662102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 400
Study 34412558 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week cognitive rehabilitation and lifestyle modifying intervention
Number of subjects: 57
Study 34412558 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 57
Study 33331183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine tablets 3.5 mg/kg
Number of subjects: 289
Study 33331183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 32935261 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy focused on Emotional Development (PCIT-ED), n = 114
Number of subjects: 229
Study 32935261 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition, n = 115
Number of subjects: 229
Study 35716852 — intervention group
Group type: EXPERIMENTAL
Intervention: Time‐restricted Feeding (TRF; restricting feeding window to 8 h/d)
Number of subjects: 32
Study 35716852 — intervention group
Group type: COMPARATOR
Intervention: Early Time‐restricted Feeding (eTRF; eating majority of kcals before 5pm)
Number of subjects: 32
Study 35716852 — intervention group
Group type: COMPARATOR
Intervention: Alternate Day Fasting (ADF; complete fasting every other day)
Number of subjects: 32
Study 35716852 — intervention group
Group type: COMPARATOR
Intervention: Weight loss and energy intake across all diets (TRF, ADF, eTRF)
Number of subjects: 32
Study 32056815 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly yoga sessions
Number of subjects: 79
Study 32056815 — intervention group
Group type: COMPARATOR
Intervention: No yoga (control group)
Number of subjects: 79
Study 36448959 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2400 mg/day for 12 weeks
Number of subjects: 60
Study 36448959 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 60
Study 34620311 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% glucose for supported mineral carrier (subgroup A)
Number of subjects: 39
Study 34620311 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (subgroup B)
Number of subjects: 39
Study 36040789 — intervention group
Group type: EXPERIMENTAL
Intervention: iCanCope intervention
Number of subjects: 56
Study 35272971 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery (Cambridge hybrid closed-loop algorithm)
Number of subjects: 133
Study 35272971 — intervention group
Group type: COMPARATOR
Intervention: Usual care with insulin pump therapy (control group)
Number of subjects: 133
Study 35272971 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery (FlorenceM configuration)
Number of subjects: 133
Study 35272971 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery (CamAPS FX configuration)
Number of subjects: 133
Study 35272971 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop group
Number of subjects: 133
Study 35272971 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 133
Study 33082016 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD 5 mcg
Number of subjects: 24
Study 33082016 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD 10 mcg
Number of subjects: 24
Study 33082016 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD 20 mcg
Number of subjects: 24
Study 33082016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 34758080 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiselimod 0.4 mg
Number of subjects: 78
Study 34758080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 34830743 — intervention group
Group type: EXPERIMENTAL
Intervention: Violet light-transmitting eyeglasses (VL glasses)
Number of subjects: 0
Study 34830743 — intervention group
Group type: COMPARATOR
Intervention: Conventional eyeglasses (placebo glasses)
Number of subjects: 0
Study 33010985 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg/d
Number of subjects: 0
Study 33010985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36164731 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel rehabilitation intervention
Number of subjects: 349
Study 33236763 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic remission
Number of subjects: 215
Study 33236763 — intervention group
Group type: COMPARATOR
Intervention: Persistent histologic activity
Number of subjects: 215
Study 34387014 — intervention group
Group type: EXPERIMENTAL
Intervention: New electron microscope with updated digital camera and new software for imaging and analysis
Number of subjects: 14
Study 34387014 — intervention group
Group type: COMPARATOR
Intervention: Original images measured using a separate software method
Number of subjects: 14
Study 34387014 — intervention group
Group type: COMPARATOR
Intervention: Original measurements of GBMs obtained on the laboratory's previous EM
Number of subjects: 14
Study 32856251 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc threonine chelate (80 mg zinc per kg feed)
Number of subjects: 256
Study 32856251 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc threonine chelate (80 and 120 mg zinc per kg feed)
Number of subjects: 256
Study 32856251 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc threonine chelate
Number of subjects: 256
Study 32856251 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (no zinc supplementation)
Number of subjects: 256
Study 32856251 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate (40, 80, and 120 mg zinc per kg feed)
Number of subjects: 256
Study 32856251 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial chelate (Bioplex Zn®) (40 mg zinc per kg feed)
Number of subjects: 256
Study 33930380 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg orally followed by misoprostol 800 mcg vaginally 24 hours later
Number of subjects: 291
Study 33930380 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol alone
Number of subjects: 291
Study 35121566 — intervention group
Group type: EXPERIMENTAL
Intervention: Young Person's Face IT (self-guided web-based psychosocial intervention)
Number of subjects: 189
Study 35121566 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 189
Study 34030768 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (150 mg, three times daily for 7 days)
Number of subjects: 70
Study 34030768 — intervention group
Group type: COMPARATOR
Intervention: Control (FOLFIRI plus bevacizumab without silymarin)
Number of subjects: 70
Study 35426929 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiorgan Focused Clinical Ultrasonography
Number of subjects: 0
Study 34962506 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support tool for discontinuing overnight vital sign checks
Number of subjects: 1699
Study 34962506 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1699
Study 33513929 — intervention group
Group type: EXPERIMENTAL
Intervention: 548 mg/day of polyphenols and 2 g/day of L-citrulline for 6 weeks
Number of subjects: 73